{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:59:18Z","timestamp":1788256758716,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqnz20221157"],"award-info":[{"award-number":["tsqnz20221157"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2022CX01013"],"award-info":[{"award-number":["2022CX01013"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M764115"],"award-info":[{"award-number":["2024M764115"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005085","name":"Beijing Institute of Technology","doi-asserted-by":"publisher","award":["2016-0006-M-202016"],"award-info":[{"award-number":["2016-0006-M-202016"]}],"id":[{"id":"10.13039\/501100005085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471514"],"award-info":[{"award-number":["32471514"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171394"],"award-info":[{"award-number":["32171394"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202338"],"award-info":[{"award-number":["82202338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22304106"],"award-info":[{"award-number":["22304106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201133","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:28:22Z","timestamp":1768868902000},"page":"201133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption"],"prefix":"10.1016","volume":"34","author":[{"given":"Bo","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-7245","authenticated-orcid":false,"given":"Yuanyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201133_bib1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201133_bib2","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.ymthe.2024.09.011","article-title":"Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing","volume":"32","author":"Fieni","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201133_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/1477-3163.83937","article-title":"Androgen receptor signaling in prostate cancer development and progression","volume":"10","author":"Lonergan","year":"2011","journal-title":"J. Carcinog."},{"key":"10.1016\/j.omton.2026.201133_bib4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201133_bib5","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2026.201133_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.omton.2026.201133_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201133_bib8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201133_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201133_bib10","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.omton.2026.201133_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201133_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201133_bib13","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201133_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5110","article-title":"A phase 1\/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress","volume":"41","author":"Jani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201133_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2023.41.6_suppl.19","article-title":"Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study","volume":"41","author":"Petrylak","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201133_bib16","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1038\/s41388-020-1191-x","article-title":"Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201133_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6603924","article-title":"FISH analysis of 107 prostate cancers shows that genomic deletion is associated with poor clinical outcome","volume":"97","author":"Yoshimoto","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201133_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/modpathol.2009.69","article-title":"Fluorescence hybridization study shows association of deletion with rearrangement during prostate cancer progression","volume":"22","author":"Han","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.omton.2026.201133_bib19","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ijc.22359","article-title":"Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis","volume":"120","author":"Schmitz","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201133_bib20","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201133_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1146\/annurev-biochem-082411-113907","article-title":"PTEN","volume":"83","author":"Worby","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omton.2026.201133_bib22","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.96.11.6199","article-title":"PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt protein kinase B signaling pathway","volume":"96","author":"Sun","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201133_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ng782","article-title":"Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease","volume":"29","author":"Backman","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2026.201133_bib24","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1126\/science.280.5369.1614","article-title":"Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN","volume":"280","author":"Tamura","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201133_bib25","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1101\/gad.1308805","article-title":"The PTEN\/PI3K pathway governs normal vascular development and tumor angiogenesis","volume":"19","author":"Hamada","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2026.201133_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201133_bib27","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/sj.onc.1201855","article-title":"Point mutation and homozygous deletion of PTEN\/MMAC1 in primary bladder cancers","volume":"16","author":"Cairns","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201133_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ng0597-64","article-title":"Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome","volume":"16","author":"Liaw","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2026.201133_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA","volume":"2","author":"Islam","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omton.2026.201133_bib30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201133_bib31","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-024-50752-9","article-title":"Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201133_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1418","article-title":"Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia","volume":"8","author":"Hu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201133_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative Genomic Profiling of Human Prostate Cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201133_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative Genomic Profiling of Human Prostate Cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201133_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140988","article-title":"Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing\u2019s Sarcoma","volume":"10","author":"Gill","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201133_bib35","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201133_bib36","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1038\/ncomms5277","article-title":"Degradable lipid nanoparticles with predictable siRNA delivery activity","volume":"5","author":"Whitehead","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201133_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.omton.2026.201133_bib38","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molcel.2019.08.006","article-title":"PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1","volume":"76","author":"Qian","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2026.201133_bib39","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1093\/nar\/gni178","article-title":"Real-time quantification of microRNAs by stem-loop RT-PCR","volume":"33","author":"Chen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201133_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201133_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.omton.2026.201133_bib42","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.molcel.2014.02.007","article-title":"TAIL-seq: Genome-wide Determination of Poly(A) Tail Length and 3\u2032 End Modifications","volume":"53","author":"Chang","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2026.201133_bib43","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbrc.2005.12.105","article-title":"mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level","volume":"340","author":"Mockey","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omton.2026.201133_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20210146","article-title":"From structural design to delivery: mRNA therapeutics for cancer immunotherapy","volume":"4","author":"Zhou","year":"2024","journal-title":"Exploration"},{"key":"10.1016\/j.omton.2026.201133_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20230147","article-title":"A perspective of lipid nanoparticles for RNA delivery","volume":"4","author":"Ma","year":"2024","journal-title":"Exploration"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:27:39Z","timestamp":1778272059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000093"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201133","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201133"}}